December 7, 2020

VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance Mail Stop 3010 100 F Street, N.E. Washington, D.C. 20549

Attention: Margaret Schwartz

Re: GALERA THERAPEUTICS, INC.

Registration Statement on Form S-3 (Registration No. 333-251061)

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-3 (Registration No. 333-251061) (the "Registration Statement") of Galera Therapeutics, Inc. (the "Company"). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Eastern Time, on December 9, 2020, or at such later time as the Company or its counsel may orally request via telephone call to the staff. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Nathan Ajiashvili at (212) 906-2916.

If you have any questions regarding the foregoing, please do not hesitate to contact Nathan Ajiashvili at (212) 906-2916, of Latham & Watkins LLP. Thank you in advance for your consideration.

Very truly yours,

GALERA THERAPEUTICS, INC.

By: /s/ Christopher Degnan

Name: Christopher Degnan Title: Chief Financial Officer

cc: Nathan Ajiashvili, Latham & Watkins LLP